Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IncobotulinumtoxinA for Chemotherapy Induced Peripheral Neuropathy
NCT03571334Phase 2Unknown
- Sponsor
- Medical College of Wisconsin
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing IncobotulinumtoxinA with Saline Placebo (2 arms). Primary endpoint: Change in Neuropathic Pain Scale at 8 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03571334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571334.